Skip to main content
GeneralHomeInvestorsNewsUzedy

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

By April 28, 2023March 15th, 2024No Comments1 min read